FilingReader Intelligence
Zydus gains US approval for celecoxib capsules
July 15, 2025 at 07:03 PM UTC•By FilingReader AI
Zydus Lifesciences announced final USFDA approval for celecoxib capsules in 50mg, 100mg, 200mg, and 400mg strengths. The pain and inflammation treatment had annual US sales of $122.6m as of May 2025.
The approval brings Zydus's total USFDA approvals to 428.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:ZYDUSLIFE•Bombay Stock Exchange
News Alerts
Get instant email alerts when Zydus Lifesciences publishes news
Free account required • Unsubscribe anytime